ACUTE TOCOLYSIS FOR FETAL DISTRESS - TERBUTALINE VERSUS MAGNESIUM-SULFATE

被引：21

作者：

MAGANN, EF

CLEVELAND, RS

DOCKERY, JR

CHAUHAN, SP

MARTIN, JN

MORRISON, JC

机构：

[1] Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Mississippi Medical Center

来源：

AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY | 1993年 / 33卷 / 04期

关键词：

D O I：

10.1111/j.1479-828X.1993.tb02109.x

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Forty-six women in active labour who developed fetal distress requiring abdominal delivery were randomized to receive 0.25 mg of terbutaline (subcutaneously) or magnesium sulphate as a 4-g bolus (intravenously) to decrease uterine activity. The terbutaline-treated group in contrast to the magnesium sulphate-treated group had reduced uterine activity as measured by Montevideo units (p <0.002). This decrease in uterine activity was noted more rapidly in all 23 patients who received terbutaline, 1.8 +/- 0.74 minutes compared to 7.5 +/- 2.1 minutes in the 16 of 23 patients (magnesium sulphate-treated women) in whom a decrease in uterine activity occurred (p <0.001). Umbilical cord arterial blood pH at delivery was less than 7.20 in only 2 of the 23 patients treated with terbutaline versus 7 of the 23 in the magnesium sulphate-treated group. We conclude that terbutaline is an effective and more rapid-acting tocolytic agent to arrest uterine activity prior to delivery for fetal distress.

引用

页码：362 / 364

页数：3

共 10 条

[1]

Ingemarsson I, Bengtsson B., A five‐year experience with terbutaline for preterm labor: Low rate of severe side effects, Obstet Gynecol, 66, pp. 176-180, (1985)

[2]

King JF, Grant A, Keirse MJNC, Chalmers I., Beta‐mimetics in preterm labour: An overview or the randomized controlled trials, Br J Obstet Gynaecol, 95, pp. 211-222, (1988)

[3]

Elliot JP, Magnesium sulfate as a tocolytic agent, Am J Obstet Gynecol, 147, pp. 277-284, (1983)

[4]

Spisso KR, Harbert GM, Thiagarajah S., The use of magnesium sulfate as the primary tocolytic agent to prevent premature delivery, Am J Obstet Gynecol, 142, pp. 840-845, (1982)

[5]

Chau AC, Gabert HA, Miller JM, A prospective comparison of terbutaline and magnesium for tocolysis, Obstet Gynecol, 80, pp. 847-851, (1992)

[6]

Shekarloo A, Mendez-Bauer C, Cook V., Terbutaline (intravenous bolus) for the treatment of acute intrapartum fetal distress, Am J Obstet Gynecol, 160, pp. 615-618, (1989)

[7]

Burke MS, Perreco RP, Day D, Watson JD, Havercamp AD, Intrauterine resuscitation with tocolysis. An alternative month clinical trial, J Perinatol, 9, pp. 296-300, (1989)

[8]

Reece EA, Chervenak FA, Romero R, Hobbins JC, Magnesium sulfate in the management of acute intrapartum fetal distress, Am J Obstet Gynecol, 148, pp. 104-106, (1984)

[9]

Mendez-Bauer C, Sherkarloo A, Cook V, Freese U., Treatment of acute intrapartum fetal distress by β‐2 sympathomimelics, American Journal of Obstetrics and Gynecology, 156, pp. 638-642, (1987)

[10]

Lipshitz J, Shaver DC, Anderson GD, Hexoprenaline tocolysis for intrapartum fetal distress and acidosis, J Reprod Med, 31, pp. 1023-1026, (1986)

← 1 →